Lineage Cell Therapeutics
LCTX
LCTX
92 hedge funds and large institutions have $146M invested in Lineage Cell Therapeutics in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $152M → $146M (-$6.22M)
13% less call options, than puts
Call options by funds: $127K | Put options by funds: $146K
Holders
92
Holding in Top 10
1
Calls
$127K
Puts
$146K
Top Buyers
| 1 | +$1.07M | |
| 2 | +$680K | |
| 3 | +$442K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$376K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$374K |
Top Sellers
| 1 | -$542K | |
| 2 | -$164K | |
| 3 | -$86K | |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$71.8K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$70K |